Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients [CARE DELIVERY]
Conclusion:
First-line carboplatin/etoposide is associated with similar survival and less subsequent hospital-based health care use than cisplatin/etoposide among elderly patients with ES SCLC treated in ambulatory settings.
Source: Journal of Oncology Practice - Category: Cancer & Oncology Authors: Hatfield, L. A., Huskamp, H. A., Lamont, E. B. Tags: Quality of Care, Guidelines, Small Cell, Chemotherapy CARE DELIVERY Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Health | Health Management | Lung Cancer | Medicare | Small Cell Lung Cancer | Toxicology